Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients

Greiner W, Rasch A, Koehler D, Salzberger B, Faetkenheuer G, Leidig M (2007)
CLINICAL MICROBIOLOGY AND INFECTION 13(3): 264-268.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Autor
; ; ; ; ;
Abstract / Bemerkung
The main aim of this study was to evaluate the clinical outcome and costs of nosocomial and community-acquired methicillin-susceptible Staphylococcus aureus (MSSA) or methicillin-resistant S. aureus (MRSA) bloodstream infection (BSI) in patients undergoing haemodialysis. A multicentre retrospective study was conducted that included 109 patients with end-stage renal disease and S. aureus BSI who were hospitalised in three German centres between 1999 and 2005. Nosocomial and community-acquired infections were analysed separately with regard to costs and outcome. Forty-nine (45%) patients had nosocomial infection. Compared to patients with community-acquired infection, these patients were more likely to have had BSI caused by MRSA (40.8% vs. 13.3%, p < 0.05). BSI was the initial reason for admission for 33 (55%) patients who had community-acquired infection. The mean length of hospitalisation was 24 days for patients with community-acquired infection and 51 days for patients with nosocomial infection (p < 0.05). Costs per treatment episode were 20 024 Euros for nosocomial infection vs. 9554 Euros for community-acquired infection (p < 0.05). The average treatment costs for patients with MSSA BSI were < 50% of those for patients with MRSA BSI (10 573 vs. 24 931 Euros, p < 0.05). S. aureus BSI is an underlying cause of substantial health risk and high morbidity among the haemodialysis-dependent population, who are already at high-risk for other reasons. This study also highlighted differences according to the source of BSI, including costs arising from hospitalisation and treatment.
Erscheinungsjahr
Zeitschriftentitel
CLINICAL MICROBIOLOGY AND INFECTION
Band
13
Ausgabe
3
Seite(n)
264-268
ISSN
eISSN
PUB-ID

Zitieren

Greiner W, Rasch A, Koehler D, Salzberger B, Faetkenheuer G, Leidig M. Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients. CLINICAL MICROBIOLOGY AND INFECTION. 2007;13(3):264-268.
Greiner, W., Rasch, A., Koehler, D., Salzberger, B., Faetkenheuer, G., & Leidig, M. (2007). Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients. CLINICAL MICROBIOLOGY AND INFECTION, 13(3), 264-268. doi:10.1111/j.1469-0691.2006.01622.x
Greiner, W., Rasch, A., Koehler, D., Salzberger, B., Faetkenheuer, G., and Leidig, M. (2007). Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients. CLINICAL MICROBIOLOGY AND INFECTION 13, 264-268.
Greiner, W., et al., 2007. Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients. CLINICAL MICROBIOLOGY AND INFECTION, 13(3), p 264-268.
W. Greiner, et al., “Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients”, CLINICAL MICROBIOLOGY AND INFECTION, vol. 13, 2007, pp. 264-268.
Greiner, W., Rasch, A., Koehler, D., Salzberger, B., Faetkenheuer, G., Leidig, M.: Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients. CLINICAL MICROBIOLOGY AND INFECTION. 13, 264-268 (2007).
Greiner, Wolfgang, Rasch, A., Koehler, D., Salzberger, B., Faetkenheuer, G., and Leidig, M. “Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients”. CLINICAL MICROBIOLOGY AND INFECTION 13.3 (2007): 264-268.

20 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Protection against Staphylococcus aureus Colonization and Infection by B- and T-Cell-Mediated Mechanisms.
Zhang F, Ledue O, Jun M, Goulart C, Malley R, Lu YJ., MBio 9(5), 2018
PMID: 30327437
Reduced pro-inflammatory responses to Staphylococcus aureus bloodstream infection and low prevalence of enterotoxin genes in isolates from patients on haemodialysis.
McNicholas S, Fe Talento A, O'Gorman J, Hannan MM, Lynch M, Greene CM, Conlon PJ, Shore AC, Coleman DC, Humphreys H, Fitzgerald-Hughes D., Eur J Clin Microbiol Infect Dis 36(1), 2017
PMID: 27638007
Association between chronic hemodialysis and bloodstream infections caused by chromosomally mediated AmpC-producing Enterobacteriaceae.
Hammer KL, Stoessel A, Justo JA, Bookstaver PB, Kohn J, Derrick CB, Albrecht H, Al-Hasan MN., Am J Infect Control 44(12), 2016
PMID: 27499192
Memory Th1 Cells Are Protective in Invasive Staphylococcus aureus Infection.
Brown AF, Murphy AG, Lalor SJ, Leech JM, O'Keeffe KM, Mac Aogáin M, O'Halloran DP, Lacey KA, Tavakol M, Hearnden CH, Fitzgerald-Hughes D, Humphreys H, Fennell JP, van Wamel WJ, Foster TJ, Geoghegan JA, Lavelle EC, Rogers TR, McLoughlin RM., PLoS Pathog 11(11), 2015
PMID: 26539822
Risk factors for morbidity and mortality of bloodstream infection in patients undergoing hemodialysis: a nested case-control study.
Fram D, Taminato M, Ponzio V, Manfredi SR, Grothe C, Batista RE, Belasco A, Barbosa D., BMC Res Notes 7(), 2014
PMID: 25481650
Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence.
Tansarli GS, Karageorgopoulos DE, Kapaskelis A, Falagas ME., Expert Rev Anti Infect Ther 11(3), 2013
PMID: 23458771
Infectious complications in dialysis--epidemiology and outcomes.
Li PK, Chow KM., Nat Rev Nephrol 8(2), 2012
PMID: 22183504
The potential economic value of a Staphylococcus aureus vaccine among hemodialysis patients.
Song Y, Tai JH, Bartsch SM, Zimmerman RK, Muder RR, Lee BY., Vaccine 30(24), 2012
PMID: 22464963
Staphylococcus aureus-derived extracellular vesicles induce neutrophilic pulmonary inflammation via both Th1 and Th17 cell responses.
Kim MR, Hong SW, Choi EB, Lee WH, Kim YS, Jeon SG, Jang MH, Gho YS, Kim YK., Allergy 67(10), 2012
PMID: 22913540
High-dose cefazolin on consecutive hemodialysis in anuric patients with Staphylococcal bacteremia.
Renaud CJ, Lin X, Subramanian S, Fisher DA., Hemodial Int 15(1), 2011
PMID: 21105995
Management of gram-positive coccal bacteremia and hemodialysis.
Fitzgibbons LN, Puls DL, Mackay K, Forrest GN., Am J Kidney Dis 57(4), 2011
PMID: 21333430
On the economic impact of a regional management of multidrug-resistant bacteria.
Ried W., GMS Krankenhaushygiene interdisziplin?r 6(1), 2011
PMID: 22242104
Overview of tigecycline efficacy and safety in the treatment of complicated skin and skin structure infections - a European perspective.
Teras J, Gardovskis J, Vaasna T, Kupcs U, Pupelis G, Dukart G, Dartois N, Jouve S, Cooper A, 305 Study Group., J Chemother 20 Suppl 1(), 2008
PMID: 19036671
Management of Gram-positive bacteraemia.
Uçkay I, Harbarth S, Pittet D., Curr Opin Infect Dis 20(6), 2007
PMID: 17975404

29 References

Daten bereitgestellt von Europe PubMed Central.

Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis.
Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, Yeoh H, Law D, Robbins JB, Schneerson R, Muenz L, Fuller S, Johnson J, Fireman B, Alcorn H, Naso R., N. Engl. J. Med. 346(7), 2002
PMID: 11844850
Methicillin-resistant Staphylococcus aureus in the community: a hospital-based study.
Goetz A, Posey K, Fleming J, Jacobs S, Boody L, Wagener MM, Muder RR., Infect Control Hosp Epidemiol 20(10), 1999
PMID: 10530648
Staphylococcus aureus infections.
Lowy FD., N. Engl. J. Med. 339(8), 1998
PMID: 9709046
Staphylococcus aureus bacteremia in patients on chronic hemodialysis.
Quarles LD, Rutsky EA, Rostand SG., Am. J. Kidney Dis. 6(6), 1985
PMID: 4073020
Bacteremia in patients on chronic hemodialysis. A multicenter prospective survey.
Kessler M, Hoen B, Mayeux D, Hestin D, Fontenaille C., Nephron 64(1), 1993
PMID: 8502343
Prospective surveillance for primary bloodstream infections occurring in Canadian hemodialysis units.
Taylor G, Gravel D, Johnston L, Embil J, Holton D, Paton S; Canadian Hospital Epidemiology Committee. Canadian Nosocomial Infection Surveillance Program., Infect Control Hosp Epidemiol 23(12), 2002
PMID: 12517012
Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis.
Engemann JJ, Friedman JY, Reed SD, Griffiths RI, Szczech LA, Kaye KS, Stryjewski ME, Reller LB, Schulman KA, Corey GR, Fowler VG Jr., Infect Control Hosp Epidemiol 26(6), 2005
PMID: 16018428
Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis.
Marr KA, Sexton DJ, Conlon PJ, Corey GR, Schwab SJ, Kirkland KB., Ann. Intern. Med. 127(4), 1997
PMID: 9265426
Nosocomial bloodstream infections in United States hospitals: a three-year analysis.
Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP., Clin. Infect. Dis. 29(2), 1999
PMID: 10476719
The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals.
Kim T, Oh PI, Simor AE., Infect Control Hosp Epidemiol 22(2), 2001
PMID: 11232886
Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia.
Reed SD, Friedman JY, Engemann JJ, Griffiths RI, Anstrom KJ, Kaye KS, Stryjewski ME, Szczech LA, Reller LB, Corey GR, Schulman KA, Fowler VG Jr., Infect Control Hosp Epidemiol 26(2), 2005
PMID: 15756889
Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis.
Whitby M, McLaws ML, Berry G., Med. J. Aust. 175(5), 2001
PMID: 11587259
Incidence and outcome of Staphylococcus aureus bacteremia in hemodialysis patients.
Marr KA, Kong L, Fowler VG, Gopal A, Sexton DJ, Conlon PJ, Corey GR., Kidney Int. 54(5), 1998
PMID: 9844145
A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance.
Chang FY, MacDonald BB, Peacock JE Jr, Musher DM, Triplett P, Mylotte JM, O'Donnell A, Wagener MM, Yu VL., Medicine (Baltimore) 82(5), 2003
PMID: 14530781
Long-term outcome and quality of care of patients with Staphylococcus aureus bacteremia.
Fatkenheuer G, Preuss M, Salzberger B, Schmeisser N, Cornely OA, Wisplinghoff H, Seifert H., Eur. J. Clin. Microbiol. Infect. Dis. 23(3), 2004
PMID: 14986158
Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002.
Tiemersma EW, Bronzwaer SL, Lyytikainen O, Degener JE, Schrijnemakers P, Bruinsma N, Monen J, Witte W, Grundman H; European Antimicrobial Resistance Surveillance System Participants., Emerging Infect. Dis. 10(9), 2004
PMID: 15498166
Vascular access for hemodialysis.
Schwab SJ, Harrington JT, Singh A, Roher R, Shohaib SA, Perrone RD, Meyer K, Beasley D., Kidney Int. 55(5), 1999
PMID: 10231476
Vascular access use in Europe and the United States: results from the DOPPS.
Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E, Gillespie B, Wolfe RA, Goodkin DA, Held PJ., Kidney Int. 61(1), 2002
PMID: 11786113
NKF‐K/DOQI Clinical Practice Guidelines for Vascular Access: update 2000
Anonymous, Am J Kidney Dis 37(suppl 1), 2001
EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients.
Hoen B, Paul-Dauphin A, Hestin D, Kessler M., J. Am. Soc. Nephrol. 9(5), 1998
PMID: 9596085
Risk factor analysis for long-term tunneled dialysis catheter-related bacteremias.
Jean G, Charra B, Chazot C, Vanel T, Terrat JC, Hurot JM, Laurent G., Nephron 91(3), 2002
PMID: 12119469
Preventing bacterial infections and antimicrobial resistance in dialysis patients.
Berns JS, Tokars JI., Am. J. Kidney Dis. 40(5), 2002
PMID: 12407632

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 17391380
PubMed | Europe PMC

Suchen in

Google Scholar